.tmb-1920v.png?sfvrsn=7f86faef_2 1920w)
Lilit Ghazaryan, Dep. Director, Scientific Center of Drugs & Medical Technology Expertise, National Responsible, Antimicrobial Use; Kristina Gyurjyan, AMR Focal Point, Armenia; Mery Ter-Stepanyan, Clinical Epidemiologist; Hrachuhi Ghazaryan, Pediatrician.
Supporting policy development and national action plans on antimicrobial resistance
WHO works with countries to help them develop policies and plan strategically, recognizing the need for an effective global response to antimicrobial resistance (AMR).
AMR poses a danger to humanity, animal health and the environment, with far-reaching negative consequences and devastating economic and social impacts.
AMR occurs when bacteria, parasites, viruses and fungi become resistant to antimicrobial medicines that are used to treat the infections they cause. As a result of AMR, antibiotics and other antimicrobial medicines become ineffective and infections increasingly difficult – or even impossible – to treat.
WHO supports countries to develop and implement National Action Plans (NAPs) on AMR. The purpose of a NAP is to assess the status of AMR and to identify priorities and actions for an effective response. While the majority of countries in the WHO European Region have developed a NAP, only 25% of them have allocated a budget for implementation.
In collaboration with the Evidence-informed Policy Network (EVIPNet), WHO helps policy-makers answer AMR-related policy problems by developing evidence briefs for policies. These are user-friendly, concise syntheses of the best-available global and local research evidence.
The purpose of the evidence briefs is to condense the national and regional information and distil it into 2 or 3 feasible, country-specific policy options.
Since 2017, an increasing number of countries in the WHO European Region have embarked on developing evidence briefs on AMR.
